Distinctive clinical features of human bocavirus in children younger than 2 years
- First Online:
- Cite this article as:
- Moriyama, Y., Hamada, H., Okada, M. et al. Eur J Pediatr (2010) 169: 1087. doi:10.1007/s00431-010-1183-x
- 345 Views
Background and objective
Clinical characteristics of human bocavirus (HBoV) infection have been studied worldwide, but their importance of those characteristics remains unknown. We investigated distinctive clinical features of HBoV-positive children with lower respiratory tract infection (LRTI).
Methods and results
During April 2007–July 2009, for 402 hospitalized children younger than 2 years with LRTI, we prospectively examined virus genomes in nasopharyngeal swabs for HBoV, respiratory syncytial virus (RSV), rhinovirus, metapneumovirus, parainfluenzavirus, and adenovirus. The HBoV genomes were identified in 34 patients (8.5%). Clinical and laboratory data of HBoV-positive and other virus/bacteria-negative patients (n = 18) were analyzed and compared with data of RSV-single positive patients (n = 99). The seasonal distribution of HBoV exhibits a concentration of cases during March–September, with most RSV cases occurring during winter in Japan. The minimum age of HBoV-positive patients was 5 months, although 44 patients (44%) with RSV were younger than 6 months. The main clinical features were respiratory distress and hypoxia. Hypoxia advances within 3 days after onset. The mean oxygen saturation on arrival was 92.8%, which was significantly lower than that in patients with RSV (p < 0.001). White blood cell counts were similar among groups. However, the percentage of neutrophils in white blood cells were significantly higher in HBoV-positive patients (62 vs. 45%, p < 0.001). Their prognoses were good. Their hospital stays were 6.6 days.
HBoV-single positive patients show several clinical characteristics, such as seasonality, age, hypoxia, and neutrophilia, which differ from those with RSV infection.
KeywordsHuman bocavirusRespiratory syncytial virusLower respiratory tract infectionInfant
Pneumonia and other lower respiratory tract infections (LRTIs) are a major cause of mortality and morbidity in infants and young children . During the past decade, detection of various respiratory viruses has improved by virtue of new molecular techniques and the availability of monoclonal antibodies for many viral species. New viruses such as human metapneumovirus (hMPV) , severe acute respiratory syndrome coronavirus (SARS-CoV) [11, 16, 23], and human bocavirus (HBoV) are reportedly major pathogens of human respiratory infection.
Since the detection of HBoV from respiratory tract samples from Swedish infants and children with LRTI , reports related to HBoV have been published around the world. Epidemiological data show that HBoV is present on every continent with different incidence rates and seasonality. In fact, HBoV is detected year round, with rates of 0.5–19% in patients with LRTI [2, 7, 13, 15, 26]. Recently, this virus is propagated in an in vitro culture system . No animal model of infection has been established. Nevertheless, the fact that HBoV is not detected randomly in materials but is detected significantly more often in the absence of other viruses suggests that HBoV is a causative agent of previously unexplained respiratory tract infections .
Several epidemiological and clinical investigations have assessed HBoV-related illness; its clinical features have been reported as resembling those of respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) infections . Nevertheless, few data are available related to physical characteristics and clinical severity for children with HBoV-positive LRTIs . To determine precise clinical characteristics in HBoV-positive patients, we prospectively collected numeric data for the clinical status of young children with LRTI and analyzed them. Results showed several unique physical characteristics in HBoV-positive patients that differed significantly from those in RSV-positive patients.
Patients and methods
The study population comprised 402 children younger than 2 years who were hospitalized with lower respiratory tract disease at some time during March 2007–July 2008 (248 male, mean age 11.6 months ± standard deviation 6.5). Informed consent was obtained from parents or guardians. Of the patients, 93 (23.2%) were younger than 6 months. This study was approved by the Ethical Committee of Tokyo Women’s Medical University (#1492).
On admission, the medical history and physical characteristics of the children were recorded systematically. For this study, LRTI was defined as the presence of wheezing, crackling rales, dyspnea, and/or obstruction of the airways, with or without fever. All patients with suspected LRTI underwent chest radiography. Pneumonia was defined as the presence of focal infiltration or consolidation in the lung by chest radiography. Blood samples were obtained to measure quantities of whole white blood cells (WBCs) as well as neutrocytes, lymphocytes, monocytes, and eosinophils. Serum samples were obtained to measure C-reactive proteins.
Oxygen saturation of the children was monitored during the hospital stay. Oxygen therapy was provided to achieve oxygen saturation ≥95%. A physician judged the bronchodilator use and administration of antibiotics for each patient according to physical findings and laboratory data.
Nucleic acid extraction and amplification
A nasopharyngeal swab was collected from each patient and then dipped into saline and stored at −80°C until nucleic acid extraction. Nucleic acid was extracted using a kit (High Pure Viral Nucleic Acid Kit; Roche Diagnostics Corp., Mannheim, Germany) according to the manufacturer’s recommended procedures. Then PCR/reverse-transcription PCR (RT-PCR) was performed using previously described methods with slight modifications [1, 3, 4, 9, 22, 24]. Briefly, for the RNA viruses, a superscript one-step RT-PCR system (Invitrogen Corp., Carlsbad, CA, USA) was used for reverse-transcription and first-round PCR with virus specific primers under the manufacturer’s instructions. For DNA viruses and also nested PCR, Ex Taq DNA polymerase (Takara Bio Inc., Shiga, Japan) was used along with the manufacturer’s supplied buffer under the appropriate thermal cycle conditions for each primer. Each sample was examined for RSV, rhinovirus (RV), hMPV, HBoV, adenovirus (AdV), and parainfluenzavirus (PIV). Following amplification, PCR products were separated on the 1.5% agarose gel with Tris–boric acid–EDTA buffer and visualized with SYBR-green (Cambrex Corp., Rockland, ME, USA) under a UV transilluminator. The PCR products were purified; their nucleic acid sequences were determined to confirm PCR results. Nucleotide sequences were processed using software (GENETYX) and compared to nucleotide sequences of the DNA database using a BLAST system .
All data were described as mean (m) ± standard deviation (SD). Parametric data were analyzed using Student’s t-test. A p value of <0.05 was considered statistically significant. All analyses were performed using software (JMP ver.8; SAS Institute Inc., NC, USA).
Frequency and seasonality of human bocavirus detection
Viruses detected in 402 patients under 2 years of age with lower respiratory tract infection
Patients infected with a single pathogen
Patients infected with more than one pathogen
HBoV + PIV
HBoV + RV
HBoV + HMPV
HBoV + AdV
HBoV + RSV
RSV + RV
RSV + AdV
PIV + RV
hMPV + AdV
hMPV + RV
hMPV + RSV
hMPV + PIV
AdV + RV
AdV + PIV
AdV + hMPV + RV
RSV + AdV + RV
Patients not infected with any studied pathogen
During the same study period, we prospectively collected swabs from 30 age-matched children with no respiratory symptoms and analyzed them similarly. Except for one patient, who was positive for rhinovirus, no virus was detected in these 30 children.
In hospitalized infants and young children aged 0–24 months, RSV was the most commonly detected virus. Of 402 patients, 111 were RSV-positive (27.6%). In 99 out of 111 patients with RSV, PCR results for other viruses were negative. Bocavirus was the fourth most common virus in the study population. Of the hospitalized children, 34 (8.5%) were HBoV positive. In 14 of 34 patients (41%), some other virus and HBoV were double positive (five with PIV, four with rhinovirus, two with hMPV, two with AdV, and one with RSV). In the other 20 patients (59%), PCR results for other viruses were negative. Of the 20 patients, two showed co-infection with Streptococcus pneumoniae, as diagnosed from sputum culture. We specifically examined the other 18 patients for the analysis of clinical features associated with HBoV infection.
Clinical manifestations of LRTI patients positive for human bocavirus
Clinical data in children positive with HBoV and in children positive with RSV
n = 18
n = 99
14.1 ± 5.1
8.9 ± 7.0
Gender (male %)
Diagnosis (pneumonia %)
Day on admission
3.0 ± 1.1
4.0 ± 1.4
Oxygen saturation (%)
92.8 ± 4.8
95.7 ± 2.9
Highest temperature (°C)
38.9 ± 0.8
38.7 ± 1.8
WBC (×103 cells/mm3)
11.4 ± 2.9
11.4 ± 4.6
62 ± 15
45 ± 18
2.62 ± 2.55
1.96 ± 2.95
Days in hospital (days)
6.6 ± 3.2
6.3 ± 1.8
The most common symptoms of HBoV-positive patients were cough and fever, which were found in all 18 patients (100%). High fever over 38.5°C was found in 13 patients (72%). The mean maximum temperature was 38.9 ± 0.8°C. Wheezing and respiratory distress were found in 14 patients (78%). One patient had diarrhea; the other 17 patients had no gastrointestinal manifestation.
Hypoxia was a characteristic feature in HBoV-positive patients (Table 2). On admission, the mean oxygen saturation in HBoV-positive patients was 92.8 ± 4.8%. The mean period from onset of illness to admission was 3.0 ± 1.1 days. For 17 of 18 patients, the main reason for admission was hypoxia and/or respiratory distress. Actually, 14 patients (78%) needed oxygen therapy. No patient required mechanical ventilation.
The clinical course was good except for that of one infant, who had extremely low birth weight and had chronic lung disease. The length of the hospital stay was 6.6 ± 3.2 days.
Comparison of clinical data of patients positive for HBoV with those of patients positive for RSV
We compared clinical data of the 18 patients with the data of hospitalized patients who were positive for RSV and negative for other viruses in the same study period (n = 99, Table 2).
A seasonal distribution of HBoV was noted during March–September. However, RSV was identified all year round; its epidemic peak was November–December (Fig. 1b). Age distributions of the two groups differed. One patient had HBoV at less than 6 months of age, although 44 patients with RSV (44%) were less than 6 months of age (Fig. 2b).
The period from disease onset to admission was significantly shorter among HBoV-positive patients than among RSV-positive patients (p = 0.008, Table 2). Furthermore, the mean oxygen saturation in HBoV-positive patients on admission was significantly lower than that in RSV-positive patients (p = 0.0004, Table 2). White blood cell (WBC) counts in these two groups were similar. However, the percentage of neutrophils in WBCs were significantly higher in HBoV-positive patients than in RSV-positive patients (p < 0.0001, Table 2). The C-reactive protein in HBoV-positive patients was similar to that of RSV-positive patients (Table 2).
The hospital stay lengths of the groups were similar. No patient in either group required mechanical ventilation.
This prospective study reveals several characteristics of HBoV-positive LRTI in young children: seasonality, age distribution, hypoxia, neutrophilia, and findings in chest radiography. Comparison of clinical features to those in patients with RSV infection, which is the major etiologic agent in LRTI of young children, showed that major clinical manifestations such as wheezing and respiratory distress were similar in both groups of patients. However, several physical characteristics of HBoV-positive patients differed significantly from those of RSV-positive patients. To describe clinical manifestations of children with LRTIs with HBoV clearly, we selected HBoV-positive and other virus/bacteria-negative patients.
Regarding the HBoV seasonality, its peak was similar to that identified in a previous study in northern Japan. In the study, HBoV-positive patients were most prevalent during January–May. The peak occurred during April–May in Japan . The seasons are important diagnostic information in Japan. In France, the seasonal distribution is November–June; the peak occurs in March–April , which resembles the circumstances in Japan. In Hong Kong and Thailand, the peak seasons were in fall and winter, respectively [8, 14].
Specific examination of extremely young patients revealed a clear difference in the age distribution of HBoV-positive patients from that of RSV. In RSV-positive patients, 44% of all patients were younger than 6 months. In contrast, the minimum age of HBoV-positive patients was 5 months. Endo et al. measured the levels of the antibody in human serum samples aged from 0 months to 41 years and reported that the seropositive rate was lowest in the age group of 6–8 months . These data suggest that infants younger than 6 months might be protected from HBoV infection.
The main clinical features in HBoV-positive patients are respiratory distress and hypoxia, which are frequently observed in LRTI patients with RSV. In our study, oxygen saturation on admission shows that hypoxia was more severe in HBoV-positive patients than in RSV-positive patients. Moreover, the short duration from disease onset to admission shows that respiratory distress and hypoxia progress rapidly in HBoV-positive patients. Oikawa et al. recently reported a severe case with HBoV associated with plastic bronchitis, which necessitated mechanical ventilation . Many previous reports have not described severe cases of HBoV infection; however, the sample size is small and the studies were retrospective. In our study, one out of 18 patients had severe pneumonia and remained hospitalized for 19 days. A larger number of cases with HBoV-positive LRTI must be accumulated to discuss the disease severity. Patients with RSV infection sometimes need intensive care. Pediatricians have specifically addressed the care and protection of this infection. One reason is that the RSV infection is frequently found in infants who are younger than 3 months. Furthermore, patients younger than 3 months often require intensive care. In contrast, the minimum age of HBoV-positive patient is 5 months in our study. Therefore, the difference in the age of patients might affect the disease severity.
Laboratory data show that the rate of neutrophils in WBCs is significantly higher in HBoV-positive patients, which is a unique characteristic of HBoV-positive LRTI. It is particularly interesting that the rate of neutrophils in hMPV-positive patients is similar to that in RSV-positive patients (data not shown). This parameter might strongly support clinical diagnosis of LRTI with HBoV. Acute hypoxia induces a differential response in peripheral blood neutrophils and lymphocytes, resulting in neutrophilia and lymphopenia . Hypoxia might be associated with neutrophilia in HBoV-positive patients. However, the precise mechanisms for neutrophilia remain unclear.
Recently, a high co-infection rate is under discussion in HBoV-positive respiratory infection [17, 18]. Previous reports have presented the possibility that HBoV detection in respiratory tract samples reflects asymptomatic persistence or prolonged viral shedding . Although results of the present study also show a high co-infection rate, clinical characteristics in HBoV-single positive patients strongly suggest the pathogenic potential of HBoV in young children with LRTIs.
This study did not survey all respiratory viruses such as coronavirus or influenza virus. Quantification of viral loads might provide useful information, especially information that would be useful to analyze co-infection cases more clearly.
In conclusion, the results of our study support that HBoV is an important causative agent in young children hospitalized with LRTI in Japan. In young children, HBoV-positive patients show several clinical characteristics that differ from those with RSV. More cases should be examined to confirm clinical manifestations and prognoses of HBoV-associated LRTIs.
This study was supported by a grant from the Japanese Society for Pediatric Infectious Diseases (H.H.) and by a grant from the Chiba Serum Institute Memorial Fund (H.H.).
Conflict of interest
The authors declare no conflict of interest.
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.